The preferential anticancer effect on pediatric malignancies by mesencymal stem cells

2014 Fiscal Year Final Research Report

• Project/Area Number: 23591541
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Pediatrics
• Research Institution: Osaka University (2012-2014); Okayama University (2011)
• Principal Investigator: MIYAMURA Takako 大阪大学, 医学(系)研究科(研究院), 特任助教(常勤) (20379796)
• Co-Investigator(Kenkyū-buntansha): HASHII Yoshiko 大阪大学, 大学院医学系研究科, 講師 (60343258) ; NANBA Noriyuki 大阪大学, 大学院医学系研究科, 講師 (10379076) ; YAMASHITA Nobuko 岡山大学, 医歯(薬)学総合研究科, 助教 (40379798) ; WASHIO Kana 岡山大学, 大学病院, 助教 (10379802)
• Project Period (FY): 2011-04-28 – 2015-03-31
• Keywords: 間葉系幹細胞 / 小児 / 悪性腫瘍

Outline of Final Research Achievements

Mesenchymal stem cells (MSC) have the capacity to differentiate into several tissues. Furthermore, it has reported that MSC could target the injured part including cancer. We investigated the enhancement of anti-tumor effects of anticancer drugs for Ewing Sarcoma (EWS) by administration of MSC. We use the EWS cell line by coculture of MSC and anticancer drugs, and evaluate the enhancement of anti-tumor effects by apoptosis assay. It had the tendency to enhance the anti-tumor effects although there was no significant difference. The antitumor effects tended to enhance depending on the concentration of MSC. We should investigate the more detailed analysis of the mechanism of MSC and antitumor effects.

Free Research Field

血液悪性腫瘍